Acalabrutinib (ACP-196) in Combination with ACP-319, for Treatment of B-Cell Malignancies

Study identifier:ACE-LY-001

ClinicalTrials.gov identifier:NCT02328014

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies

Medical condition

Non-Hodgkins Lymphoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Acalabrutinib, ACP-319

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 20 Dec 2014
Primary Completion Date: 01 Jun 2020
Estimated Study Completion Date: 01 Apr 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

AstraZeneca

Inclusion and exclusion criteria